Adjuvant radiotherapy, chemotherapy, and endocrine and HER2‐guided therapy are all clinical strategies that can significantly reduce the risk of disease recurrence and improve the overall survival rate of patients with breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.